Effect of bauhinia bauhinioides kallikrein inhibitor on endothelial proliferation and intracellular calcium concentration.

OBJECTIVES Proteinase inhibitors act as a defensive system against predators e.g. insects, in plants. Bauhinia bauhinioides kallikrein inhibitor (BbKI) is a serine proteinase inhibitor, isolated from seeds of Bauhinia bauhinioides and is structurally similar to plant Kunitz-type inhibitors but lacks disulfide bridges. In this study we evaluated the antiproliferative effect of BbKI on endothelial cells and its impact on changes in membrane potential and intracellular calcium. MATERIALS AND METHODS HUVEC proliferation was significantly reduced by incubation with BbKI 50 and 100 µM 12% and 13%. Furthermore, BbKI (100 µM) exposure caused a significant increase in intracellular Ca2+ concentration by 35% as compared to untreated control. RESULTS The intracellular rise in calcium was not affected by the absence of extracellular calcium. BBKI also caused a significant change in the cell membrane potential but the antiproliferative effect was independent of changes in membrane potential. CONCLUSIONS BBKI has an antiproliferative effect on HUVEC, which is independent of the changes in membrane potential, and it causes an increase in intracellular Ca2+.

[1]  S. S. Andrade,et al.  Bauhinia bauhinioides cruzipain inhibitor reduces endothelial proliferation and induces an increase of the intracellular Ca2+ concentration , 2010, Journal of Physiology and Biochemistry.

[2]  L. Chao,et al.  Tissue kallikrein promotes prostate cancer cell migration and invasion via a protease-activated receptor-1-dependent signaling pathway , 2010, Biological chemistry.

[3]  M. Sampaio,et al.  Action of plant proteinase inhibitors on enzymes of physiopathological importance. , 2009, Anais da Academia Brasileira de Ciencias.

[4]  B. Wienecke,et al.  Apigenin‐induced nitric oxide production involves calcium‐activated potassium channels and is responsible for antiangiogenic effects , 2007, Journal of thrombosis and haemostasis : JTH.

[5]  K. Ohlsson,et al.  High-Dose intraperitoneal aprotinin treatment of acute severe pancreatitis: A double-blind randomized multi-center trial , 1994, Journal of Gastroenterology.

[6]  C. Schäfer,et al.  Quercetin-induced induction of the NO/cGMP pathway depends on Ca2+-activated K+ channel-induced hyperpolarization-mediated Ca2+-entry into cultured human endothelial cells. , 2005, Planta medica.

[7]  J. Rehbock,et al.  Identification of immunoreactive tissue kallikrein in human ductal breast carcinomas , 2005, Journal of Cancer Research and Clinical Oncology.

[8]  Gene Kwan,et al.  Binding, proteolytic, and crystallographic analyses of mutations at the protease-inhibitor interface of the subtilisin BPN'/chymotrypsin inhibitor 2 complex. , 2004, Biochemistry.

[9]  E. Diamandis,et al.  The emerging roles of human tissue kallikreins in cancer , 2004, Nature Reviews Cancer.

[10]  I. Polikarpov,et al.  Crystal structure of an unusual Kunitz-type trypsin inhibitor from Copaifera langsdorffii seeds , 2004 .

[11]  T. Neumann,et al.  Statins prevent oxidized low-density lipoprotein- and lysophosphatidylcholine-induced proliferation of human endothelial cells. , 2004, Vascular pharmacology.

[12]  Lee Chao,et al.  Kallistatin is a new inhibitor of angiogenesis and tumor growth. , 2002, Blood.

[13]  H. Itoh,et al.  Emerging multifunctional aspects of cellular serine proteinase inhibitors in tumor progression and tissue regeneration , 2002, Pathology international.

[14]  L. Chao,et al.  A synthetic tissue kallikrein inhibitor suppresses cancer cell invasiveness. , 2001, The American journal of pathology.

[15]  I. Polikarpov,et al.  Crystallization and preliminary X-ray diffraction analysis of a novel trypsin inhibitor from seeds of Copaifera langsdorffii. , 2001, Acta crystallographica. Section D, Biological crystallography.

[16]  M. Juliano,et al.  Bauhinia bauhinioides plasma kallikrein inhibitor: interaction with synthetic peptides and fluorogenic peptide substrates related to the reactive site sequence. , 2001, Current medicinal chemistry.

[17]  B. Nilius,et al.  Ion channels and their functional role in vascular endothelium. , 2001, Physiological reviews.

[18]  K. Bhoola,et al.  Kallikrein and kinin receptor genes. , 2000, Pharmacology & therapeutics.

[19]  D. Nicol,et al.  The human tissue kallikreins (KLKs 1-3) and a novel KLK1 mRNA transcript are expressed in a renal cell carcinoma cDNA library. , 1999, Immunopharmacology.

[20]  Z. Dlamini,et al.  Visualisation of tissue kallikrein and kinin receptors in oesophageal carcinoma. , 1999, Immunopharmacology.

[21]  J. Clements,et al.  Tissue kallikrein and the bradykinin B2 receptor are expressed in endometrial and prostate cancers. , 1997, Immunopharmacology.

[22]  L. Chao,et al.  Molecular cloning, purification and in situ localization of human colon kallikrein. , 1995, The Biochemical journal.

[23]  K. Bhoola,et al.  Bioregulation of kinins: kallikreins, kininogens, and kininases. , 1992, Pharmacological reviews.

[24]  R. Huber,et al.  Natural protein proteinase inhibitors and their interaction with proteinases. , 1992, European journal of biochemistry.

[25]  C. Figueroa,et al.  Characterization of a tissue kallikrein in human prolactin-secreting adenomas. , 1990, The Journal of endocrinology.

[26]  David John Adams,et al.  Ion channels and regulation of intracellular calcium in vascular endothelial cells , 1989, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[27]  I. Kato,et al.  Protein inhibitors of proteinases. , 1980, Annual review of biochemistry.

[28]  E. Jaffe,et al.  Culture of human endothelial cells derived from umbilical veins. Identification by morphologic and immunologic criteria. , 1973, The Journal of clinical investigation.